Results 131 to 140 of about 18,037 (235)

A Novel NR3C1 Frameshift Variant Associated With Familial Glucocorticoid Resistance Syndrome: An Integrated Analysis of Steroid Profiling and Structural Modeling

American Journal of Medical Genetics Part A, Volume 200, Issue 12, Page 2719-2737, December 2026.
ABSTRACT Glucocorticoid resistance syndrome (GRS) is a rare hereditary disorder caused by pathogenic variants in NR3C1, characterized by marked phenotypic heterogeneity and frequent misdiagnosis as primary aldosteronism or subclinical Cushing's syndrome.
Sufang Yun, Zhifeng Zhu, Fengye Zhou, Ying Liu, Chunfang Liang, Haitao Ju, Lin Lu, Zhaoli Yan   +7 more
wiley   +1 more source

Negative Prognostic Impact of Mineralocorticoid Receptor Antagonist in Elderly Patients Receiving TAVR. [PDF]

J Clin Med, 2023
Imamura T, Narang N, Onoda H, Tanaka S, Ushijima R, Sobajima M, Fukuda N, Ueno H, Kinugawa K.   +8 more
europepmc   +1 more source

How developmental stressors affect mitochondrial respiratory function: a systematic review and meta‐analysis

Biological Reviews, Volume 101, Issue 6, Page 2756-2779, December 2026.
ABSTRACT The environmental conditions organisms experience during early development can have powerful and sustained effects on morphology, physiology, behaviour, and performance. Such developmental effects can influence reproductive success, survival, and life‐history strategies and can be transmitted across generations (i.e.
Ondi L. Crino, Christopher R. Friesen, Geoffrey E. Hill, Dalton C. Leibold, Pablo Recio, Karine Salin, Kristoffer H. Wild, Daniel W.A. Noble   +7 more
wiley   +1 more source

Correction: The mineralocorticoid receptor antagonist finerenone enhances cardiovascular recovery upon food intake normalization in obese mice. [PDF]

Cardiovasc Diabetol
Monmirel-Fauconnier M, Pieronne-Deperrois M, Bonnard B, Frimat C, Linghui K, Dheasmhunaigh AN, Nicol L, Morchid S, Renet S, Dumesnil A, Richard V, Fève B, Jaisser F, Boulkroun S, Mulder P, Ouvrard-Pascaud A.   +15 more
europepmc   +1 more source

Therapies for Cardiovascular‐Kidney‐Liver‐Metabolic Syndrome: Reappraisal of Fibrates

Diabetes, Obesity and Metabolism, Volume 28, Issue 12, Page 10931-10949, December 2026.
ABSTRACT Cardiovascular disease, chronic kidney disease (CKD), type 2 diabetes mellitus (T2DM), obesity and metabolic dysfunction‐associated steatohepatitis (MASH) frequently coexist and share overlapping pathophysiology, forming the proposed cardiovascular‐kidney‐liver‐metabolic (CKLM) syndrome.
Virginia Anagnostopoulou, Christoforos K. Travlos, Lucas Lage Marinho, Thomas A. Mavrakanas, João Pedro Ferreira, Abhinav Sharma   +5 more
wiley   +1 more source

The SGLT2i Treatment Gap in UK Primary Care: A Cross‐Sectional RWE Study of Prescribing in Clinical Practice

Diabetes, Obesity and Metabolism, Volume 28, Issue 12, Page 11278-11287, December 2026.
ABSTRACT Aims Sodium‐glucose co‐transporter 2 inhibitors (SGLT2i) improve cardiovascular and renal outcomes in type 2 diabetes mellitus (T2DM), chronic kidney disease (CKD) and chronic heart failure (CHF). Despite clinical guideline recommendations, SGLT2i uptake in UK primary care remains suboptimal and information on utilisation is limited.
Chelsea Stefanska, Ryan Chung, Salman Ramjaun, Danyao Jin, Ciara Doherty, Kieran McCafferty, Samuel Seidu   +6 more
wiley   +1 more source

The non-steroidal mineralocorticoid receptor antagonist finerenone and heart failure with preserved ejection fraction. [PDF]

Cardiovasc Diabetol, 2023
Kintscher U, Edelmann F.
europepmc   +1 more source

Effects of Renin–Angiotensin Inhibitors, Sodium–Glucose Cotransporter 2 Inhibitors, Mineralocorticoid Receptor Antagonists and Glucagon‐Like Peptide 1 Receptor Agonists on Kidney Outcomes in Patients With Type 1 Diabetes: A Systematic Review and Meta‐Analysis

Diabetes, Obesity and Metabolism, Volume 28, Issue 12, Page 11320-11327, December 2026.
ABSTRACT Aims While the new kidney protective therapies have transformed chronic kidney disease (CKD) management in patients with Type 2 diabetes mellitus (T2DM), treatment options for CKD in Type 1 diabetes mellitus (T1DM) have remained unchanged for 30 years, limited to renin–angiotensin system inhibitors (RASis).
Frances Perry, Silvia J. Leon, Kate Polecina, Ruth Getachew, Nicole Askin, Thomas Ferguson, Reid Whitlock, Zihe Zheng, Carolina Aldworth, Arvind Katta, Jacob Earl, Mauricio Beller Ferri, Navdeep Tangri   +12 more
wiley   +1 more source

Potassium binders and continuation of renin-angiotensin system inhibitors/mineralocorticoid receptor antagonist in chronic kidney disease and heart failure (the DEMONSTRATE database). [PDF]

J Intern Med
Furuland H, Larsson AO, Uhde M, Parv K, Almstedt M, Cars T, Svensson MK.   +6 more
europepmc   +1 more source

Mineralocorticoid Receptor Antagonists and Acute Heart Failure [PDF]

European Journal of Heart Failure, 2019
Carlos, Escobar, Luis, Manzano
openaire   +2 more sources